Zentalis Pharmaceuticals, Inc. (ZNTL) research
Zentalis Pharmaceuticals, Inc.- Sector
- Biotechnology
- Last price
- $2.52
- As of
Zentalis Pharmaceuticals, Inc. (ZNTL): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-14.
As of . Source: SEC EDGAR filings for ZNTL. Method and limitations.
Share the ZNTL intelligence card
See the full ZNTL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZNTL on one page. Preview it with sample data, then open it live with a free account.
Preview the ZNTL dossierActive signals for ZNTL
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 96% of ZNTL (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of ZNTL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +699% to ZNTL (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 63% of ZNTL (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 18.1%, EPS $-0.59 vs $-0.4997 estimate
FREE, NO ACCOUNT
Every signal on ZNTL, as it fires
You are seeing 5 of 11 signals recorded on ZNTL since 2026-05-31.
The five above landed across 2 days. The other 6 were recorded on 3 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZNTL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 98943L107 · 2026Q2 | $14.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 98943L107 · 2026Q2 | $11.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 98943L107 · 2026Q2 | $7.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 98943L107 · 2026Q2 | $3.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 98943L107 · 2026Q2 | $2.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZNTL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ZNTL against its peers
ZNTL's return on equity of -63.4% ranks in the 43rd percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ZNTL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 52.7M USD | 6 | 17 |
| Revenue YoY | n/a | -15.9% | n/a | 5 |
| Operating margin | n/a | -203.1% | n/a | 18 |
| Net margin | n/a | -265.2% | n/a | 19 |
| Return on equity | -63.4% | -26.9% | 43 | 21 |
Peers (24): IVVD, SLGL, BCYC, LCTX, SION, PRQR, LYEL, MGNX, PALI, CAMP, IFRX, KROS, RNAC, ANIK, NWBO, NAGE, CGEN, PLX, ANTX, STRO, IMRX, GLSI, WHWK, ACIU. Left out: VCRE (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZNTL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ZNTL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZNTLand get the insider, 13F, options, and confluence read in one view.